-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a recent announcement by Brii Biosciences, the company will be officially listed on the Hong Kong Stock Exchange today (July 13)
Tengshengbo Pharmaceutical was established in 2017, focusing on the treatment of chronic diseases that cause a major public health burden
Through the combination of internal drug R&D and introduction licensing, Tengshengbo Pharmaceutical has established a R&D pipeline consisting of more than 10 innovative product candidates
According to the prospectus, the net proceeds of Tengshengbo Pharmaceutical’s IPO will be mainly used for the development of products under research, especially the core product hepatitis B virus (HBV) functional cure project, human immunodeficiency virus (HIV) project, and multi-drug resistant (MDR) or extensively drug-resistant (XDR) Gram-negative infections projects
1.
BRII-179 (VBI-2601): It is a new recombinant protein immunotherapy candidate drug developed by VBI Vaccines company in the clinical research stage.
BRII-835 (VIR-2118): is an experimental RNAi drug, administered by subcutaneous injection, can effectively silence all HBV RNA transcripts
According to the prospectus, BRII-179 and BRII-835 have different mechanisms of action, and the combination of drugs is expected to maximize the synergy of antiviral and host protective immune response, thus becoming a functional cure for chronic HBV infection.
2.
Tengshengbo Pharmaceutical is developing BRII-778 and BRII-732 as a single-tablet combination therapy once a week, in order to provide more cautious, convenient and non-invasive maintenance therapy for HIV patients
Among them, BRII-778 is a non-nucleoside reverse transcriptase inhibitor Edurant (ripivirine hydrochloride) extended release (ER) preparation, BRII-732 is a new chemical entity that can be metabolized into EFdA or islatravir ( An experimental drug for the treatment of HIV infection)
3.
Public information shows that Tengshengbo Pharmaceutical has cooperated with Tsinghua University and Shenzhen Third People's Hospital to develop two fully human non-competitive neutralizing antibodies: BRII-196 and BRII-198
.
They can non-competitively recognize unique epitopes in the SARS-CoV-2 spike protein RBD.
This strategy can reduce the chance of producing drug-resistant viruses during antibody therapy, thereby increasing the possibility of antibody binding to future virus variants
.
The researchers also modified the crystallizable fragment region (Fc segment) of each antibody to extend the antibody's half-life
.
At present, Tengshengbo Pharmaceutical is rapidly advancing the BRII-196/BRII-198 cocktail therapy
.
On April 29, Tengshengbo Pharmaceutical announced that the combination therapy has entered the phase 3 clinical ACTIV-2 study, which is aimed at outpatients with new crowns who are at high risk of disease progression
.
In addition, Tengshengbo Pharmaceutical's research pipeline also covers other disease areas, including central nervous system diseases, multi-drug resistant Gram-negative bacterial infections, and postpartum depression
.
Earlier, Dr.
Hong Zhi, founder and CEO of Tengsheng Biopharmaceuticals, said in an interview with WuXi AppTec's content team that highly pathogenic infectious diseases can cause deaths in a short period of time, and affect people as much as cancer.
Major diseases
.
At present, the pathology research progress is relatively slow for most acute infectious diseases caused by viruses
.
Humans have developed a large number of antibiotics against bacterial infections, but have not yet found powerful broad-spectrum antiviral drugs, and the world is facing the threat of drug-resistant bacteria
.
Tengshengbo Pharmaceutical will be committed to introducing the world's excellent anti-infective innovative technologies and therapies, exploring better research and development models for infectious disease drugs, and benefiting patients as soon as possible
.
We congratulate Tengsheng Bo Pharmaceutical on the Hong Kong Stock Exchange and enter a new stage of development
.
It is hoped that with the help of the capital market, the company will bring innovative treatments to patients as soon as possible and contribute to solving public health problems
.
